Intravenous Immunoglobulins for Prevention of BKV Viremia in Kidney TransplantRecipients According to BKV genotype-specific Neutralizing Antibody Titers at theday of transplantation: A Multicenter Study -BKANIG - 6997

es Hopitaux Universitaires De Strasbourg0 个研究点目标入组 664 人开始时间: 2024年6月20日最近更新: 2024年7月22日

试验速览

暂无简介。

•Adult patients (= 18 years), Kidney transplant recipients, including multiple organ transplant patients, Patients able to understand the purpose and the risks of the study, fully informed and having written informed consent, Affiliated to a medical insurance scheme

•BKV nephropathy during a previous transplantation in the past 5 years, Patients with isolated IgA deficiency French, HLA and ABO-incompatible kidney transplant recipients undergoing desensitization with rituximab and/or plasmapheresis before transplantation or susceptible to receive such therapy after transplantation, Patients with high risk of post- transplant Focal Segmental glomerulosclerosis recurrence, Patient with hyperprolinemia, Contraindications to the use to IVIg: hypersensitivity to the active substance or to any excipients or human immunoglobulins, especially in patients with antibodies against IgA, Pregnant or breast feeding women, Adults under guardianship or limited guardianship, Currently participating in another clinical trial investigating drugs (observational studies are not considered as an exclusion criterion), Patients with high risk of thrombosis

发起方

es Hopitaux Universitaires De Strasbourg